Corcept Therapeutics | CORT - Equity Capital And Reserves


Corcept Therapeutics reported $647.8M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alaunos Therapeutics USD 2.8M 858K Sep/2025
ANI Pharmaceuticals USD 540.72M 34.91M Dec/2025
Ardelyx USD 154.28M 14.75M Sep/2025
Assertio Holdings USD 105.8M 12.5M Sep/2025
Aurora Cannabis CAD 567.1M 21.58M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 736.01M 247.04M Sep/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
J&J USD 78.47B 0 Sep/2025
Knight Therapeutics CAD 766.79M 3.74M Sep/2025
Lexicon Pharmaceuticals USD 107.54M 12.62M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Novartis USD 44.33B 2.28B Sep/2025
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 693.11M 34.1M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025